Terlipressin Acetate Powder CAS14636-12-5

 Terlipressin Acetate Powder CAS14636-12-5

Product Info

Product Name: Terlipressin Acetate

M.F.:  C52H74N16O15S2

CAS: 14636-12-5

M.W: 1227.37

EINECS: 238-680-8

Grade: pharma Grade

Shelf life: 2 years

Purity:99%

Appearance: white to off-white

Product Introduction:

Terlipressin acetate is a vasopressin analogue with potent vasoactiveproperties. Terlipressin acetate is a highly selective vasopressin V1 receptoragonist that reduces the splanchnic blood flow and portal pressure andcontrols acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects.

Terlivasopressin, whose chemical name is triglycolyllysine vasopressin, is a new synthetic long-acting vasopressin preparation. It is a precursor drug, inactive on its own, which is used in vivo by aminopeptidase as Chemicalbook. After the removal of three glycinyl residues at its N-terminal, terlivasopressin slowly "releases" active lysine vasopressin, so terlivasopressin acts as a reservoir that releases lysine vasopressin at a steady rate


Function & Application:
 

Terlivasopressin is a new synthetic long-acting vasopressin preparation, which belongs to a kind of precursor drug, and is inactive in itself. After removing three glycinyl residues at the n-terminal of terlivasopressin in vivo, active lysine vasopressin is slowly "released". It is this "slow release" mechanism that enables it to maintain smooth muscle contraction for up to 10 hours after a single dose of vasopressin, whereas an equivalent dose of vasopressin can maintain its activity for only 20-40 minutes. On the other hand, due to the slow enzymatic hydrolysis rate, the circulating lysine vasopressin can not reach the toxic level, so the use of terlivasopressin is relatively safe. The pharmacological effect of terlivasopressin is to systole the vascular smooth muscle of the viscera and reduce the blood flow of the viscera (such as reducing the blood flow of the mesentery, spleen, uterus, etc.), thus reducing the blood flow of the Chemicalbook portal vein and reducing the pressure of the portal vein. On the other hand, terlivasopressin can also reduce the effect of the plasma renin concentration, so as to increase the renal blood flow of patients with hepatorenal syndrome. Improves renal function and urine volume. Vasopressin is currently the only can increase the mortality of esophagus varicosity burst hemorrhage in patients with drugs, before is mainly used in the clinical treatment of varicose veins rupture hemorrhage, besides trey vasopressin now also has been successfully used for comprehensive, hepatorenal coexist refractory shock, is also likely to play a useful role in cardiopulmonary resuscitation (CPR). Compared with vasopressin, it is durable, does not cause dangerous complications, including fibrinolysis and serious complications of cardiovascular system, and is simple to use (can be injected intravenously), so it is more suitable for the rescue and treatment of acute and severe patients.

 Other Peptide API&Intermediate

 Other Cosmetic Peptide Products

Why Choose Us:

1.Stable quality, high quality satisfy customer's high grade sourcing request.
2.Competitive price .
3.Correct delivery time promise.
4.Continuous improvement make sure the long-term cooperation.
5.Honest service for your whole sourcing process.

Welcome your inquiry and cooperation ,feel free to contact with us !

Contact us:
Call us by 0086-13675847137
Email at jayjie@hjyy.com
QQ:1430571263